Business Wire

Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical -stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry ...
Yahoo Finance

Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular ...

Company will present early clinical data from the first cohort of dry AMD patients at the 77 th annual Wills Eye Conference in Philadelphia on March 6, 2025 FORT LEE, N.J., February 18, ...
Business Wire

Luxa Biotechnology Presents Clinical Data from First-in-Human Retinal Pigment Epithelium Cell Therapy Trial for Dry Age-Related Macular Degeneration at the 77th Annual Wills ...

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing a novel adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related ...
PharmiWeb

Luxa Biotechnology Announces Publication in Cell Stem Cell Describing Positive Clinical Results for First-in-Human Clinical Trial for Dry AMD Therapy

FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology LLC (Luxa), a clinical-stage biotechnology company developing novel adult retinal pigment epithelial stem cell (RPESC) therapies for dry age-related ...
Nasdaq

Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA)

Nasdaq provides updated worldwide news headlines. Here you can find up-to-the-minute news and analysis of the company that you are researching for potential investment opportunities.
Nasdaq

Lux Health Tech Acquisition Corp. Class A Common Stock (LUXA)

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...